Gastroenterology · Proton Pump InhibitorRegulatory Approvalregulatorymid-term

FDA Grants Approval for Rabeprazole Sodium ANDA204237

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/22/2026, 6:32:02 PM

Assessment confidence: 70% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Rabeprazole Sodium ANDA204237 is significant as it strengthens Rubicon Research's competitive position in the gastroenterology market. This event necessitates a strategic assessment of market dynamics and potential shifts in market share among proton pump inhibitors. Regulatory context from FDA (FDA AP — RABEPRAZOLE SODIUM (SUPPL)) supports the near-term read. Assessment grounded in 19 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and consider strategies to leverage the new product offering. The strongest clinical anchor is A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults (ClinicalTrials.gov), sponsor/company relevance (pfizer). In Gastroenterology · Proton Pump Inhibitor, 8 regulatory and 3 competitive items passed relevance filtering for Rabeprazole Sodium.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Grants Priority Review for Pfizer's Marstacimab (BLA761369). This approval may enhance Rubicon Research's position in the gastroenterology market, particularly against other proton pump inhibitors.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — RABEPRAZOLE SODIUM (SUPPL) (FDA). Entity match (rabeprazole sodium); Regulatory pathway relevance (nda). This approval indicates compliance with FDA standards, which may influence future submissions and regulatory strategies for similar products.

Key Risks

Elevated medium regulatory exposure for Rabeprazole Sodium could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval could lead to increased market share for Rubicon Research, impacting revenue streams and competitive positioning against established proton pump inhibitors.
Portfolio teams should assess the impact of this approval on market share and consider strategies to leverage the new product offering.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and any competitive responses from other proton pump inhibitor manufacturers.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — RABEPRAZOLE SODIUM (SUPPL)
FDAhigh relevance
Entity match (rabeprazole sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACETAZOLAMIDE SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Assessment of the Efficacy of Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Sodium Bicarbonate for the Treatment of Severe Metabolic Acidosis With Moderate or Severe Acute Kidney Injury in ICU
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Grants Priority Review for Pfizer's Marstacimab (BLA761369)
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
FDA Grants Approval for Tofacitinib Citrate ANDA218900 by Saptalis Pharmaceuticals
Humanexa Signalsmedium relevance
Moderate corpus alignment

Self-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Systematic identification of bacterial neuraminidase inhibitors from Psoralea corylifolia using ultrafiltration-UPLC-Q-Orbitrap-MS and molecular dynamics.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Discovery of azaindole/indole-fused pyrimidine tetracyclic scaffolds as novel potent CDK7 inhibitors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Rabeprazole Sodium

Commercial impact

medium

The approval could lead to increased market share for Rubicon Research, impacting revenue streams and competitive positioning against established proton pump inhibitors.

Regulatory impact

medium

This approval indicates compliance with FDA standards, which may influence future submissions and regulatory strategies for similar products.

What to watch

Monitor market entry timelines and any competitive responses from other proton pump inhibitor manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.